Zevra Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Neil McFarlane
Chief executive officer
US$3.4m
Total compensation
CEO salary percentage | 4.6% |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | 1.3yrs |
Board average tenure | less than a year |
Recent management updates
Recent updates
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensation vs Market: Neil's total compensation ($USD3.45M) is above average for companies of similar size in the US market ($USD1.62M).
Compensation vs Earnings: Insufficient data to compare Neil's compensation with company performance.
CEO
Neil McFarlane (50 yo)
less than a year
Tenure
US$3,445,231
Compensation
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He has served as Director at Collegi...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | less than a year | US$3.45m | no data | |
Co-Founder & Chief Development Officer | no data | US$1.67m | 0.065% $ 123.0k | |
CFO, Secretary & Treasurer | 8.8yrs | US$2.26m | 0.038% $ 71.8k | |
Chief Commercial Officer & Executive VP of Business Development | 1.3yrs | US$1.82m | 0.0084% $ 15.8k | |
Chief Scientific Officer | 1.3yrs | US$1.08m | 0.0066% $ 12.4k | |
Vice President of Investor Relations & Corporate Communications | 1.7yrs | no data | no data | |
Senior Vice President of Manufacturing | 1.3yrs | no data | no data | |
Senior Vice President of Clinical Development | 1.3yrs | no data | no data | |
Senior Vice President of Medical Affairs & Advocacy | 1.3yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | no data | |
Senior VP & Corporate Controller | 7.2yrs | no data | 0.011% $ 20.1k |
1.3yrs
Average Tenure
50.5yo
Average Age
Experienced Management: ZVRA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | less than a year | US$3.45m | no data | |
Independent Director | less than a year | US$274.00k | 0% $ 0 | |
Independent Director | less than a year | US$258.02k | 0% $ 0 | |
Independent Chair | 2.7yrs | US$324.39k | 0.0017% $ 3.3k | |
Member of Scientific and Medical Advisory Board | no data | no data | no data | |
Independent Director | less than a year | no data | 0.048% $ 90.4k | |
Independent Director | less than a year | US$260.67k | 0.0024% $ 4.5k | |
Chairman of Scientific and Medical Advisory Board | 17.3yrs | no data | no data | |
Member of Scientific & Medical Advisory Board | no data | no data | no data | |
Co-Chair of Physician Advisory Council | 10.5yrs | no data | no data | |
Co-Chair of Physician Advisory Council | 10.5yrs | no data | no data | |
Independent Director | less than a year | US$243.04k | 0.024% $ 45.2k |
1.0yrs
Average Tenure
57yo
Average Age
Experienced Board: ZVRA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.